New drug duo aims to slow lung cancer progression
NCT ID NCT06670196
First seen Jan 05, 2026 · Last updated Jun 01, 2026 · Updated 19 times
Summary
This study tests whether adding SKB264 to the standard drug osimertinib helps people with a specific type of advanced lung cancer (EGFR-mutated non-squamous non-small cell) live longer without their cancer growing. About 420 adults who have not had prior treatment for advanced disease will receive either the combination or osimertinib alone. The main goal is to see if the combination delays cancer progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-Sen University Cancer Center
NOT_YET_RECRUITINGGuangzhou, Guangdong, 510060, China
-
Sun Yat-Sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Conditions
Explore the condition pages connected to this study.